Ali Husain Ali Zayer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali Husain Ali Zayer has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Abdulkarim Y. Alaysereen
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
2 shared publications - Abdu-Alaziz Khaskieh
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
1 shared publication - Abdullah Hussain
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
1 shared publication - Aysha Al Moosa
Department of Dermatology, Salmaniya Medical Complex, Manama 329, Bahrain
1 shared publication - Bindhu Nair
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
1 shared publication - Bushra Hasan
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
1 shared publication
Latest Publications
- Open Access
Topical Insulin in Atrophic Acne Scarring: A Systematic Review of Efficacy, Safety, and Patient Satisfaction
Background: Atrophic acne scars are challenging to treat and have a negative psychological impact. Insulin has been tried as a topical adjuvant and stimulates fibroblast activity, collagen deposition, and keratinocyte migration. Objectives: To evaluate topical insulin for atrophic acne scars in terms of its effectiveness, safety, and patient-rated results. Methods: Five databases were searched for research on topical insulin, either alone or in conjunction with a procedure, without regard to the date. Records were screened, extracted, and evaluated in duplicate (RoB 2 or ROBINS-I) each by two independent researchers, using Covidence. Results: Fourteen studies with 619 patients, seven randomized and seven non-randomized, were qualified. All insulin arms improved from baseline (35.8% to 55.4%), but comparator arms mostly improved similarly; five studies, none at low risk of bias, favored insulin. Adverse effects were mostly local, minor, and transient, although one study reported systemic hypoglycemia-related symptoms; glucose monitoring was inconsistent, and satisfaction was high. Limitations: Meta-analysis was not possible due to heterogeneity in design, dosage, and outcome scales, and the small number of patients precludes certain conclusions. Conclusions: Although its superiority over current adjuncts has not been demonstrated, topical insulin appears to be an affordable, well-tolerated adjunct that may have a function where traditional therapies are unavailable; larger studies are needed.
Open AccessTopical Insulin in Atrophic Acne Scarring: A Systematic Review of Efficacy, Safety, and Patient Satisfaction
Background: Atrophic acne scars are challenging to treat and have a negative psychological impact. Insulin has been tried as a topical adjuvant and stimulates fibroblast activity, collagen deposition, and keratinocyte migration. Objectives: To evaluate topical insulin for atrophic acne scars in terms of its effectiveness, safety, and patient-rated results. Methods: Five databases were searched for research on topical insulin, either alone or in conjunction with a procedure, without regard to the date. Records were screened, extracted, and evaluated in duplicate (RoB 2 or ROBINS-I) each by two independent researchers, using Covidence. Results: Fourteen studies with 619 patients, seven randomized and seven non-randomized, were qualified. All insulin arms improved from baseline (35.8% to 55.4%), but comparator arms mostly improved similarly; five studies, none at low risk of bias, favored insulin. Adverse effects were mostly local, minor, and transient, although one study reported systemic hypoglycemia-related symptoms; glucose monitoring was inconsistent, and satisfaction was high. Limitations: Meta-analysis was not possible due to heterogeneity in design, dosage, and outcome scales, and the small number of patients precludes certain conclusions. Conclusions: Although its superiority over current adjuncts has not been demonstrated, topical insulin appears to be an affordable, well-tolerated adjunct that may have a function where traditional therapies are unavailable; larger studies are needed.
- Open Access
- 29 June 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 800
Stimuli-Responsive Nanocarriers as Next-Generation on-Demand Drug Delivery Systems for Cancer Therapy: Mechanistic Insights, Trigger Modalities, and Translational Challenges
Chemotherapy has been used in cancer treatment for decades; however, standard chemotherapy treatments still have significant weaknesses, including collateral damage to healthy tissue, rapid development of drug resistance, and dose-limiting toxicity that limits therapeutic value. There is now an alternative approach using polymer materials that are responsive to biological stimuli that will allow for improved treatment of cancer while avoiding the limitations. Responsive polymer materials are designed to be inert during circulation until they reach their site of action; then, they will respond to specific triggers. These smart carriers respond to stimuli present in the tumor microenvironment (e.g., low pH, high glutathione levels, and increased proteolytic activity) or external stimuli applied at the bedside (e.g., localized heat, light, ultrasound, and applied magnetic fields). In both cases, there is a consistent pattern where the drug is released exactly where/when it is needed, with minimal drug release occurring outside that location and timeframe. Therefore, it is theorized that the use of polymeric-based delivery systems with stimuli-regulated drug release will significantly increase the concentration of drug delivered intratumorally, decrease the drug toxicity, and provide a potential mechanism to overcome the development of multidrug resistance from a variety of cancer treatments. To date, various types of responsive polymers have been developed and could be combined to give rise to a wide variety of different vehicle systems (e.g., micelles, nanogels, hydrogels, and hybrid delivery systems), with many of these carriers designed to respond to multiple stimuli simultaneously. Nonetheless, significant challenges remain in the clinical application of these materials due to tumor heterogeneity, immune system interactions, reproducibility issues, polymer chemistry advances, surface chemistry, and other interaction mechanisms. As a result of all of these evolving regulatory systems, as well as some of the emerging areas of polymer chemistry and surface engineering, theranostic integration will allow for new routes to provide therapy for patients with cancer. Additionally, because of these scientific advances, there will also be more opportunities to provide targeted, controllable, and on-demand treatments to patients using stimuli-responsive polymers.
- 29 June 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 800
Open AccessStimuli-Responsive Nanocarriers as Next-Generation on-Demand Drug Delivery Systems for Cancer Therapy: Mechanistic Insights, Trigger Modalities, and Translational Challenges
Chemotherapy has been used in cancer treatment for decades; however, standard chemotherapy treatments still have significant weaknesses, including collateral damage to healthy tissue, rapid development of drug resistance, and dose-limiting toxicity that limits therapeutic value. There is now an alternative approach using polymer materials that are responsive to biological stimuli that will allow for improved treatment of cancer while avoiding the limitations. Responsive polymer materials are designed to be inert during circulation until they reach their site of action; then, they will respond to specific triggers. These smart carriers respond to stimuli present in the tumor microenvironment (e.g., low pH, high glutathione levels, and increased proteolytic activity) or external stimuli applied at the bedside (e.g., localized heat, light, ultrasound, and applied magnetic fields). In both cases, there is a consistent pattern where the drug is released exactly where/when it is needed, with minimal drug release occurring outside that location and timeframe. Therefore, it is theorized that the use of polymeric-based delivery systems with stimuli-regulated drug release will significantly increase the concentration of drug delivered intratumorally, decrease the drug toxicity, and provide a potential mechanism to overcome the development of multidrug resistance from a variety of cancer treatments. To date, various types of responsive polymers have been developed and could be combined to give rise to a wide variety of different vehicle systems (e.g., micelles, nanogels, hydrogels, and hybrid delivery systems), with many of these carriers designed to respond to multiple stimuli simultaneously. Nonetheless, significant challenges remain in the clinical application of these materials due to tumor heterogeneity, immune system interactions, reproducibility issues, polymer chemistry advances, surface chemistry, and other interaction mechanisms. As a result of all of these evolving regulatory systems, as well as some of the emerging areas of polymer chemistry and surface engineering, theranostic integration will allow for new routes to provide therapy for patients with cancer. Additionally, because of these scientific advances, there will also be more opportunities to provide targeted, controllable, and on-demand treatments to patients using stimuli-responsive polymers.